Blarcamesine Preserves Brain Volume and Saves 17.8 Months in Alzheimer’s Trial
Anavex’s ANAVEX2-73-AD-004 Phase IIb/III data show oral blarcamesine preserved brain volume and saved 17.8 months versus ADNI1 controls after 33.1 months of treatment. In the genetically defined ABCLEAR32 cohort, MRI-based atrophy slowing correlated with a 78% increase in R² for ADAS-Cog13, underscoring its precision medicine potential.
1. Presentation of Long-Term Phase IIb/III Data
Anavex presented analyses from its ANAVEX2-73-AD-004 Phase IIb/III trial showing that patients treated with oral blarcamesine experienced substantially slower brain atrophy, correlating with improved cognitive and functional endpoints.
2. Time Advantage Versus Historical Control
Long-term open-label extension data indicate a 17.8-month time advantage over the ADNI1 historical control after 33.1 months of treatment, highlighting potential disease-modifying effects in early Alzheimer’s disease.
3. Strengthened Precision Medicine Correlation
In the ABCLEAR32 subgroup—patients with wild-type SIGMAR1 and COL24A1 genes—the correlation between MRI-based atrophy slowing and ADAS-Cog13 scores strengthened by 78% (R² increase from 0.23 to 0.41), supporting Anavex’s precision medicine strategy.
4. Clinical and Development Implications
Anavex emphasized the convenience of oral dosing and manageable safety profile, positioning blarcamesine for further clinical development and regulatory discussions as a novel Alzheimer’s therapy.